At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase I/II Multicenter Trial of Intra-Arterial Carboplatin and Oral Temozolomide for the Treatment of Recurrent and Symptomatic Residual Brain Metastases.
In Brief
A Phase 2 clinical trial evaluating carboplatin and temozolomide for Brain Tumor and Brain Metastases. Completed, enrolled 17 participants across 1 site.
Detailed Summary
Purpose: The primary objective of this study is to determine if chemotherapy with carboplatin and temozolomide significantly affects the response rates, or size of disease, in patients with brain metastases, originating from cancer in other parts of the body, compared to patients who have already been treated with radiation. Survival, causes of death, recurrence of disease in the central nervous system, toxicity, and quality of life will all be measured as secondary objective in this study.
Study Details
Timeline
Interventions
IA carboplatin 200 mg/m2/day for each arterial injection on days 1 and 2.
150 mg/m2/day orally Days 1-5. Treatment cycles to be repeated every 4 weeks.